Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients

Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients


Dumas G, (, 2016), Blood, (Link to abstract)


The authors analyzed the effect of eculizumab, an anti-C5 monoclonal antibody, on three patients with Sickle Cell Disease (SCD) affected with delayed hemolytic transfusion reaction (DHTR) after blood transfusions. Administration of 2 doses of eculizumab led to reduction of hemolysis and vasculopathy. Despite normal C3 levels, there were signs of terminal complement activation in these patients providing a basis of the mechanisms implicated.


* Eculizumab showed efficacy on delayed hemolytic transfusion reactions in three SCD-patients and can be considered in severe cases.